JP2013535970A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013535970A5 JP2013535970A5 JP2013523612A JP2013523612A JP2013535970A5 JP 2013535970 A5 JP2013535970 A5 JP 2013535970A5 JP 2013523612 A JP2013523612 A JP 2013523612A JP 2013523612 A JP2013523612 A JP 2013523612A JP 2013535970 A5 JP2013535970 A5 JP 2013535970A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- derivative
- amino acid
- fragment
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 175
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 133
- 230000013595 glycosylation Effects 0.000 claims description 120
- 238000006206 glycosylation reaction Methods 0.000 claims description 120
- 239000000203 mixture Substances 0.000 claims description 103
- 235000000346 sugar Nutrition 0.000 claims description 93
- 150000008163 sugars Chemical class 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 41
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 32
- 210000004027 cell Anatomy 0.000 claims description 26
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 21
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 21
- 125000005629 sialic acid group Chemical group 0.000 claims description 21
- 150000007523 nucleic acids Chemical group 0.000 claims description 17
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 16
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 14
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 claims description 11
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 10
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 8
- 230000009450 sialylation Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- SUHQNCLNRUAGOO-UHFFFAOYSA-N N-glycoloyl-neuraminic acid Natural products OCC(O)C(O)C(O)C(NC(=O)CO)C(O)CC(=O)C(O)=O SUHQNCLNRUAGOO-UHFFFAOYSA-N 0.000 claims description 6
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 4
- 241000282836 Camelus dromedarius Species 0.000 claims description 3
- 241000283707 Capra Species 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 241000288906 Primates Species 0.000 claims description 3
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 3
- 101710113436 GTPase KRas Proteins 0.000 claims description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- 229940082789 erbitux Drugs 0.000 claims description 2
- 125000003147 glycosyl group Chemical group 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 230000002018 overexpression Effects 0.000 claims description 2
- 102000009929 raf Kinases Human genes 0.000 claims description 2
- 108010077182 raf Kinases Proteins 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- KPAIBEKNDBAQDX-AKKDPBBWSA-N (4S,5R,6R)-5-amino-2,4-dihydroxy-3-(2-hydroxyacetyl)-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid Chemical compound C(CO)(=O)C1C(C(O)=O)(O)O[C@H]([C@@H]([C@H]1O)N)[C@H](O)[C@H](O)CO KPAIBEKNDBAQDX-AKKDPBBWSA-N 0.000 claims 1
- 238000004904 shortening Methods 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 6
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 6
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
- 229960005395 cetuximab Drugs 0.000 description 3
- 229940126618 pankomab Drugs 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- 229960000548 alemtuzumab Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229950007874 solanezumab Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2010/004878 | 2010-08-10 | ||
| EP2010004878 | 2010-08-10 | ||
| PCT/EP2011/063791 WO2012020065A1 (en) | 2010-08-10 | 2011-08-10 | Fab-glycosylated antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016149616A Division JP2016185169A (ja) | 2010-08-10 | 2016-07-29 | Ｆａｂグリコシル化抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013535970A JP2013535970A (ja) | 2013-09-19 |
| JP2013535970A5 true JP2013535970A5 (enExample) | 2014-09-25 |
| JP6334166B2 JP6334166B2 (ja) | 2018-05-30 |
Family
ID=44674756
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013523612A Active JP6334166B2 (ja) | 2010-08-10 | 2011-08-10 | Ｆａｂグリコシル化抗体 |
| JP2016149616A Withdrawn JP2016185169A (ja) | 2010-08-10 | 2016-07-29 | Ｆａｂグリコシル化抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016149616A Withdrawn JP2016185169A (ja) | 2010-08-10 | 2016-07-29 | Ｆａｂグリコシル化抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9359439B2 (enExample) |
| EP (1) | EP2603528B1 (enExample) |
| JP (2) | JP6334166B2 (enExample) |
| CN (1) | CN103119064B (enExample) |
| AU (1) | AU2011288464B2 (enExample) |
| BR (1) | BR112013003095B1 (enExample) |
| CA (1) | CA2805984C (enExample) |
| DK (1) | DK2603528T3 (enExample) |
| ES (1) | ES2605304T3 (enExample) |
| PL (1) | PL2603528T3 (enExample) |
| PT (1) | PT2603528T (enExample) |
| WO (1) | WO2012020065A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9051370B2 (en) | 2010-08-10 | 2015-06-09 | Glycotope Gmbh | Humanized EGFR antibodies |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| US9580511B2 (en) | 2013-03-11 | 2017-02-28 | Genzyme Corporation | Site-specific antibody-drug conjugation through glycoengineering |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| CA2908819A1 (en) * | 2013-04-22 | 2014-10-30 | Glycotope Gmbh | Anti-cancer treatments with anti-egfr antibodies having a low fucosylation |
| HUE061339T2 (hu) | 2014-03-19 | 2023-06-28 | Genzyme Corp | Targetáló csoportok helyspecifikus glikotechnikai átalakítása |
| JP2017528468A (ja) * | 2014-09-10 | 2017-09-28 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ガラクトース操作型免疫グロブリン１抗体 |
| CA2944085C (en) * | 2014-09-16 | 2018-04-10 | Ease Charm Limited | Anti-egfr antibody and uses of same |
| PL3204425T3 (pl) | 2014-10-09 | 2021-03-08 | Genzyme Corporation | Glikomodyfikowane koniugaty przeciwciał z lekami |
| US11306139B2 (en) * | 2015-03-20 | 2022-04-19 | Ablynx N.V. | Glycosylated immunoglobulin single variable domains |
| WO2017162733A1 (en) * | 2016-03-22 | 2017-09-28 | Glycotope Gmbh | Iga antibodies with enhanced stability |
| US20190343953A1 (en) * | 2017-01-27 | 2019-11-14 | Glycotope Gmbh | Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor |
| SG11201907288RA (en) | 2017-02-28 | 2019-09-27 | Seattle Genetics Inc | Cysteine mutated antibodies for conjugation |
| WO2019090424A1 (en) * | 2017-11-09 | 2019-05-16 | National Research Council Of Canada | Antibody glycoconjugates and methods of production and use |
| EP3794042B1 (en) | 2018-05-18 | 2024-03-27 | Daiichi Sankyo Co., Ltd. | Anti-muc1- exatecan antibody-drug conjugate |
| JP7575401B2 (ja) | 2019-04-03 | 2024-10-29 | ジェンザイム・コーポレーション | 断片化が低減した抗アルファベータｔｃｒ結合ポリペプチド |
| BR112023005152A2 (pt) * | 2020-09-21 | 2023-04-25 | Systimmune Inc | Anticorpo biespecífico com especificidade intensificada (seba) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| GB9200415D0 (en) | 1992-01-09 | 1992-02-26 | Bagshawe Kenneth D | Inactivation of cytotoxic drugs |
| US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
| WO2003016466A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
| AU2003217912A1 (en) | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| CA2535489C (en) | 2003-08-14 | 2014-09-30 | D. Collen Research Foundation Vzw | Antibodies against factor viii with modified glycosylation in the variable region |
| DK1654353T3 (da) | 2003-08-18 | 2013-08-26 | Glycotope Gmbh | Tumorcellelinjerne nm-f9 (dsm acc2606) og nm-d4 (dsm acc2605) samt anvendelser deraf |
| CA2557725C (en) | 2004-02-13 | 2015-06-30 | Glycotope Gmbh | Highly active glycoproteins-process conditions and an efficient method for their production |
| US20060051353A1 (en) * | 2004-05-14 | 2006-03-09 | Jean-Frederic Colombel | Methods and compositions to evaluate antibody treatment response |
| AU2006247039B2 (en) * | 2005-05-19 | 2011-03-03 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
| CN101506238B (zh) * | 2005-06-30 | 2013-11-06 | 森托科尔公司 | 具有提高治疗活性的方法和成分 |
| GB0519398D0 (en) * | 2005-09-23 | 2005-11-02 | Antisoma Plc | Biological materials and uses thereof |
| US20090181016A1 (en) * | 2005-11-30 | 2009-07-16 | University Of Southern California | FCgamma POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME |
| WO2008028686A2 (en) * | 2006-09-10 | 2008-03-13 | Glycotope Gmbh | Use of human cells of myeloid leukaemia origin for expression of antibodies |
| WO2008101177A2 (en) * | 2007-02-16 | 2008-08-21 | University Of Virginia Patent Foundation | Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis |
| EP2283043B1 (en) * | 2008-04-07 | 2014-08-13 | Bayer HealthCare, LLC | Methods of recombinant production of glycoproteins |
| KR20110016959A (ko) * | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| EP2281844A1 (en) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC 1 antibodies |
| US9051370B2 (en) * | 2010-08-10 | 2015-06-09 | Glycotope Gmbh | Humanized EGFR antibodies |
-
2011
- 2011-08-10 EP EP11760415.7A patent/EP2603528B1/en active Active
- 2011-08-10 ES ES11760415.7T patent/ES2605304T3/es active Active
- 2011-08-10 AU AU2011288464A patent/AU2011288464B2/en not_active Ceased
- 2011-08-10 CN CN201180039635.7A patent/CN103119064B/zh not_active Expired - Fee Related
- 2011-08-10 PL PL11760415T patent/PL2603528T3/pl unknown
- 2011-08-10 JP JP2013523612A patent/JP6334166B2/ja active Active
- 2011-08-10 BR BR112013003095-0A patent/BR112013003095B1/pt not_active IP Right Cessation
- 2011-08-10 PT PT117604157T patent/PT2603528T/pt unknown
- 2011-08-10 DK DK11760415.7T patent/DK2603528T3/en active
- 2011-08-10 WO PCT/EP2011/063791 patent/WO2012020065A1/en not_active Ceased
- 2011-08-10 US US13/816,390 patent/US9359439B2/en active Active
- 2011-08-10 CA CA2805984A patent/CA2805984C/en active Active
-
2016
- 2016-07-29 JP JP2016149616A patent/JP2016185169A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019204236B2 (en) | Tri-specific binding molecules and methods of use thereof | |
| US20210206851A1 (en) | LAG-3-Binding Molecules and Methods of Use Thereof | |
| JP7620807B2 (ja) | 抗ＳＩＲＰα抗体およびその適用 | |
| HK1252829A1 (zh) | 促进抗原消除的抗原结合分子 | |
| JP7257971B6 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| CN117024593A (zh) | 抗SIRPα抗体 | |
| US20050142133A1 (en) | Optimized proteins that target the epidermal growth factor receptor | |
| BR112021003156A2 (pt) | composição, anticorpo que se liga ao tigit humano, formulação farmacêutica, polinucleotídeo isolado, vetor, célula hospedeira, métodos para a produção de um anticorpo que se liga ao tigit humano e de anticorpos afucosilados que se ligam a tigit e para o tratamento de um câncer, e, kit. | |
| CA3020864A1 (en) | Novel b7-h3-binding molecules, antibody drug conjugates thereof and methods of use thereof | |
| JP2021525544A5 (enExample) | ||
| HUE034276T2 (en) | Bispecific anti-IGF-1R and anti-ErbB3 antibodies | |
| JP2013528357A5 (enExample) | ||
| JP6633520B2 (ja) | プロアポトーシス活性を有するヒトｉｇｇ１由来抗体 | |
| JP2015533853A5 (enExample) | ||
| JP2019527194A5 (enExample) | ||
| WO2025111585A1 (en) | Engineered bispecific molecules and methods of use | |
| KR20230098317A (ko) | 표적 세포가 제한되는, 공동자극, 이중특이적 및 2가 항-cd28 항체 | |
| RU2822496C1 (ru) | АНТИТЕЛО К SIRPα И ЕГО ПРИМЕНЕНИЕ | |
| WO2026064545A1 (en) | Engineered tl1a targeting regions and methods of use | |
| WO2021115465A1 (en) | Antibodies binding rankl and uses thereof | |
| HK40064910A (en) | Tri-specific binding molecules and methods of use thereof | |
| JP2025533189A (ja) | 上皮増殖因子受容体バリアントｉｉｉ抗体 | |
| TW202613173A (zh) | 多特異性抗cd40/抗fap抗體及其用途 | |
| HK1235796B (en) | Tri-specific binding molecules and methods of use thereof | |
| EA041483B1 (ru) | Связывающие lag-3 молекулы и способы их применения |